Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Jun. 30, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 26,039	$ 4,612
Short-term investments	57,571	46,490
Prepaid expenses and other current assets	3,611	5,027
Total current assets	87,221	56,129
Operating lease asset, net	621	365
In-process research and development	32,386	32,386
Other assets	255	186
Total assets	120,483	89,066
Current liabilities:
Accounts payable	2,148	967
Current operating lease liabilities	269	383
Accrued expenses and other liabilities	3,608	2,545
Total current liabilities	6,025	3,895
Deferred tax liabilities	1,752	1,752
Non-current operating lease liabilities	386
Warrant liabilities	120,821	76,211
Total liabilities	128,984	81,858
Commitments and contingencies (Note 8)
Stockholders' equity (deficit):
Common stock, $0.001 par value, 200,000,000 shares authorized at June 30, 2024 and December 31, 2023; 38,506,614 and 24,213,130 shares issued and outstanding at June 30, 2024 and December 31, 2023, respectively	39	24
Additional paid-in capital	379,400	326,586
Accumulated deficit	(387,940)	(319,402)
Total stockholders’ equity	(8,501)	7,208
Total liabilities and stockholders' equity (deficit)	120,483	89,066
Series X1 Non-voting Convertible Preferred Stock [Member]
Stockholders' equity (deficit):
Preferred stock, value
Series X Non-voting Convertible Preferred Stock [Member]
Stockholders' equity (deficit):
Preferred stock, value

In-process research and development.

No definition available.

Name:	eldn_InProcessResearchAndDevelopment
Namespace Prefix:	eldn_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).